Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer.

Juan JinBin LiJianing CaoTing LiJian ZhangJun CaoMingchuan ZhaoLeiping WangBiyun WangZhonghua TaoXi-Chun Hu

Published in: Journal of translational medicine (2023)

After correcting for HR expression, only marginal differences in clinical and molecular phenotypes were determined between HER2-low and HER2-zero breast cancer. Therefore, HER2-low breast cancer is insufficient to be defined as a distinct molecular entity, but rather a heterogenous disease.

Keyphrases

poor prognosis
gene expression
single molecule
dna methylation
copy number
genome wide